StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.36−0.04 (-8.94%)

Close on Nov 17, 2026Market cap $87.79MP/E –Yield –

Outlook Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Outlook Therapeutics's price to sales ratio was 3.2× on Jan 31, 2020, against 17.9× a year earlier. Over the last 3 years it ranged from 2.1× to 32.9×, with a median of 13.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2020Jan 31, 20203.2×+1.2
2019Dec 31, 20192.1×−9.6
2018Dec 31, 201811.7×+3.2
2017Dec 29, 20178.5×−14.5
2016Dec 30, 201623.0×–

More Outlook Therapeutics figures

See a number that looks wrong?